Allergan Aesthetics, an AbbVie company, announces it has entered into an agreement with Luminera, a privately held, aesthetics company based in Israel with a portfolio and pipeline of dermal filler products. 

Under the terms of the agreement, Allergan Aesthetics will acquire Luminera’s full dermal filler portfolio and R&D pipeline further enhancing Allergan Aesthetics’ leading dermal filler portfolio with its JUVEDERM collection of fillers, AbbVie notes in a media release. 

“The addition of the Luminera assets adds innovative technology, complementing our leading JUVEDERM filler franchise. We welcome the Luminera team as we continue to build our global aesthetics company and a world-class product offering for healthcare professionals and patients around the world.”

— Carrie Strom, SVP, AbbVie, and President, Global Allergan Aesthetics

“We believe bringing together key, innovative Luminera assets with the support of Allergan Aesthetics will provide an even brighter future for our people, products and a more expanded offering for our customers. This is a tremendous opportunity to further build, develop and collaborate with a leading global aesthetics company.”

— Luminera Chairman Dadi Segal, PhD

Will Continue to Develop HArmonyCa

Luminera’s key value driver for the future is HArmonyCa, an innovative dermal filler intended for facial soft tissue augmentation comprised of a combination of cross-linked hyaluronic acid (HA) with embedded calcium hydroxyapatite (CaHA) microspheres. The combination of HA and CaHA in a single product is highly differentiated in the dermal filler category. HArmonyCa is currently commercially available in Israel and Brazil.

Allergan Aesthetics will continue to develop this product for its International and US markets, per the release.

The Luminera dermal filler portfolio also includes a line of HA dermal fillers, as well CaHA based fillers commercialized across several markets. Brands include Crystalys, Hydryalix and Hydryal.

[Source(s): AbbVie, PR Newswire]

Related Content:
Evolus Botox Rival Loses First Round Over AbbVie’s Allergan
FDA Approves the Chin Filler JUVÉDERM VOLUMA XC from Allergan Aesthetics
Comply with Regulations, FDA Warns Allergan and Ideal Implant